Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
about
Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family membersCaveolinopathies: from the biology of caveolin-3 to human diseasesModulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1CThe ZZ domain of dystrophin in DMD: making sense of missense mutations.Sarcospan reduces dystrophic pathology: stabilization of the utrophin-glycoprotein complex.From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies.Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotypeLimb-girdle muscular dystrophies--from genetics to molecular pathology.Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteinsViral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advancesMembrane targeting and stabilization of sarcospan is mediated by the sarcoglycan subcomplex.Nanospan, an alternatively spliced isoform of sarcospan, localizes to the sarcoplasmic reticulum in skeletal muscle and is absent in limb girdle muscular dystrophy 2F.Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.Sarcospan: a small protein with large potential for Duchenne muscular dystrophyDelta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamstersPTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.Lipid raft in cardiac health and disease.Caveolae, caveolin, and cavins: potential targets for the treatment of cardiac disease.ABC of multifaceted dystrophin glycoprotein complex (DGC).Inhibition of lipid raft-dependent signaling by a dystrophy-associated mutant of caveolin-3.Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.Dystroglycan is not required for localization of dystrophin, syntrophin, and neuronal nitric-oxide synthase at the sarcolemma but regulates integrin alpha 7B expression and caveolin-3 distribution.Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro.Localization of the human caveolin-3 gene to the D3S18/D3S4163/D3S4539 locus (3p25), in close proximity to the human oxytocin receptor gene
P2860
Q24290252-F78451C3-12F6-4197-8F42-266073453A9BQ24599074-94F0CB69-0AE7-4754-BCA9-BEAE834A64E6Q28506016-9E2E4F0C-76C7-4569-92CA-FBA12758F787Q34094400-1D2C8E13-E160-4A51-B9C7-5AEA6D2D8B89Q34871548-5FAC68FF-D04F-41EB-A531-CBFCD7273AAAQ35166268-7F413153-14B2-46D1-AF7B-34DC7090EC0CQ35212451-AE439B99-6FDF-4A0A-9278-FADAC0792070Q35714351-9917A29E-2D23-4B11-BB16-341F51910C9EQ35792179-DFC286FB-DB22-410C-A526-4FDDAEC1AB9CQ35847178-DC1053AF-EAE1-48D0-9869-1421BA1DBDB7Q36288396-2C159C34-5682-4EF5-8C10-9799186C53CFQ36394350-0465D876-ED08-438B-A2E5-F825D1CB2E20Q36422465-A97F8E42-4E5E-4465-9571-06C33E63CFFFQ36690397-14862136-D8DA-4F51-B4F5-B115C2B53AC5Q37092093-66EE9127-07FD-4E1A-A78E-3EEFA804146FQ37164566-EA4F1E24-6357-4AE0-B6CC-2C1A41318B36Q37740972-AE80948D-12B4-4324-8104-FF6E9CBAC85CQ37886183-E68690A4-05E7-416A-A16D-081406D5DEEFQ39278570-A34E2993-8885-4759-8573-F11FC176FBCAQ40746067-5438C87A-9F7A-42EA-8139-702BE7CB921BQ42162757-D602EB92-EBC9-40DB-8A13-930EBFE15F83Q42797699-1E0CFF89-DCA0-4F16-B76E-B0F036F8142AQ42811534-6C0A9469-48DB-4459-ADBC-1A67EB0EA8C9Q43821631-59FFA267-F5D2-4693-8641-E382330476F6Q46769731-ED271F41-14A1-40DD-ADDE-73189CCAD40FQ56551673-3C9B4483-64C8-485A-963A-54BD9E0E65D0
P2860
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
@en
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
@nl
type
label
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
@en
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
@nl
prefLabel
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
@en
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
@nl
P2093
P1433
P1476
Caveolin-3 is not an integral component of the dystrophin glycoprotein complex.
@en
P2093
P304
P356
10.1016/S0014-5793(98)00442-6
P407
P577
1998-05-01T00:00:00Z